Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists

Abstract

Most of reported steroidal FXR antagonists are restricted due to low potency. We described the design and synthesis of novel nonsteroidal scaffold SIPI-7623 derivatives as FXR antagonists. The most potent compound A-11 (IC = 7.8 ± 1.1 μM) showed better activity compared to SIPI-7623 (IC = 40.8 ± 1.7 μM) and guggulsterone (IC = 45.9 ± 1.1 μM). Docking of A-11 in FXR's ligand-binding domain was also studied.